Securities code: Allgens Medical Technology Co.Ltd(688613) securities abbreviation: Allgens Medical Technology Co.Ltd(688613) Announcement No.: 2022015 Allgens Medical Technology Co.Ltd(688613) shareholders’ reduction of shares
Plan announcement
The board of directors, all directors and relevant shareholders of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law. Important content tips:
Basic information of shareholding of major shareholders
As of the disclosure date of this announcement, the shareholder of Allgens Medical Technology Co.Ltd(688613) (hereinafter referred to as “the company” or ” Allgens Medical Technology Co.Ltd(688613) “) Beijing Qilun Tianyou Venture Capital Co., Ltd. (hereinafter referred to as “Qilun Tianyou”) holds 12090933 shares of the company, accounting for 9.07% of Allgens Medical Technology Co.Ltd(688613) total shares; Bioveda China RMB investment Limited (hereinafter referred to as “bioveda”) holds Allgens Medical Technology Co.Ltd(688613) 11759347 shares, accounting for 8.82% of Allgens Medical Technology Co.Ltd(688613) total shares; Jiaxing Huakong equity investment fund partnership (limited partnership) (hereinafter referred to as “Jiaxing Huakong”) holds Allgens Medical Technology Co.Ltd(688613) 12976445 shares, accounting for 9.73% of Allgens Medical Technology Co.Ltd(688613) total shares. The above shares are the shares obtained by Qilun Tianyou, bioveda and Jiaxinghua before the company’s initial public offering and listing, and will be listed and circulated from May 23, 2022.
Main contents of share reduction plan
The company recently received the notification letter on share reduction plan issued by Qilun Tianyou, bioveda and Jiaxing Huakong. Due to their own capital arrangement, Qilun Tianyou, bioveda and Jiaxing Huakong will reduce their shares through centralized bidding and block trading according to the market conditions:
Qilun Tianyou plans to reduce Allgens Medical Technology Co.Ltd(688613) shares by means of centralized bidding and block trading to no more than 3590933 shares, accounting for 2.69% of Allgens Medical Technology Co.Ltd(688613) total shares. Among them, the reduction through centralized bidding shall be implemented within 3 months after 15 trading days from the date of issuance of the reduction plan (June 14, 2022 to September 13, 2022); In case of reduction through block trading, it shall be implemented within 3 months after 2 trading days from the date of issuance of the reduction plan (from May 25, 2022 to August 24, 2022).
Bioveda plans to reduce Allgens Medical Technology Co.Ltd(688613) shares by no more than through centralized bidding and block trading
4000000 shares, accounting for 3% of Allgens Medical Technology Co.Ltd(688613) total shares. Among them, if the holdings are reduced through centralized bidding, they will be reduced automatically
Within 3 months after 15 trading days from the date of issuance of the holding plan (June 14, 2022 to September 20, 2022)
(June 13); If the holdings are reduced through block trading, it shall be 2 trading days from the date of issuance of the reduction plan
It will be implemented within 3 months after (from May 25, 2022 to August 24, 2022).
Jiaxing Huakong plans to reduce Allgens Medical Technology Co.Ltd(688613) shares by no more than through centralized bidding and block trading
6488223 shares, accounting for 4.87% of Allgens Medical Technology Co.Ltd(688613) total shares. Among them, if the shares are reduced through centralized bidding,
Within 6 months after 15 trading days from the date of issuance of the reduction plan (June 14, 2022 to 2022)
(December 13, 2014); If the holdings are reduced through block trading, it shall be delivered within 2 months from the date of issuance of the reduction plan
It will be implemented within 6 months after the exchange date (from May 25, 2022 to November 24, 2022).
Jiaxing Huakong has submitted shares to China in accordance with the special provisions on the reduction of shares held by shareholders of venture capital funds of listed companies
The fund industry association has applied for preferential policies for the reduction of venture capital funds, and the number and proportion of reduction will be in strict accordance with relevant laws
Laws and regulations and the provisions approved by the fund industry association shall be implemented.
1、 Basic information of the reducing entity
Shareholder name shareholder identity shareholding number (shares) shareholding proportion current shareholding source
More than 5% obtained before non first IPO: 9.07% of Qilun Tianyou 12090933
Major shareholder shares
More than 5% obtained before non first IPO: 11759347bioveda 117593478.82%
Major shareholder shares
More than 5% obtained before the largest IPO: 12976445 Jiaxing Huakong 129764459.73%
Shareholder shares
There is no concerted action of the above subjects.
Major shareholders have not reduced their shares since listing.
2、 Main contents of share reduction plan
Planned reduction planned reduction competitive trading reduction reasonable proposed reduction shareholder name proposed reduction method
Quantity (share) holding proportion price range share source reason during reduction period
Qilun Tianyou no more than: no more than bidding transaction minus 2022 / 6 / 14. Take its own capital before IPO at the market price
359093 over: hold, no more than: ~ gedejin arranged 3 shares, 2.69% 3590933 shares, 2022 / 9 / 13
Block trading minus
Hold, not exceeding:
3590933 shares
Bioveda no more than: no more than bidding transaction minus 2022 / 6 / 14. Take its own capital 400000 before IPO at the market price. More than: 3%, no more than: ~ gedejin arranges 0 shares, 4000000 shares, 2022 / 9 / 13
Block trading minus
Hold, not exceeding:
4000000 shares
Jiaxing Huakong no more than: no more than bidding transaction minus 2022 / 6 / 14, taking its own capital 648822 before IPO according to the market price, no more than: ~ gedejin arranges 3 shares 4.87%, 6488223 shares 2022 / 12 / 1
Block trading minus 3
Hold, not exceeding:
6488223 shares
(I) whether the relevant shareholders have other arrangements □ yes √ no
(II) major shareholders’ previous opinions on shareholding ratio, shareholding quantity, shareholding period, reduction method, reduction quantity and reduction
Whether the holding price has made a commitment √ yes □ no
Commitment of Qilun Tianyou, bioveda and Jiaxing Huakong on share circulation restriction and locking:
“Do not transfer or entrust others to manage the shares held by the unit within 12 months from the date of listing of the company’s shares
The shares issued before the company’s public offering of shares shall not be repurchased by the company.
For the shares increased due to ex rights and ex dividend of the above locked shares, the unit will also abide by the above locking commitments.
If they fail to fulfill the above commitments, they will voluntarily accept the regulatory measures given by the Shanghai Stock Exchange and other regulatory authorities in accordance with relevant regulations. “
Whether the proposed reduction is consistent with the previously disclosed commitments √ yes □ no
(III) whether it is a non-profit company at the time of listing, and its controlling shareholders, actual controllers, directors, supervisors and senior managers plan to reduce their pre IPO shares □ yes √ no
(IV) other matters required by the exchange
3. The controlling shareholder or actual controller reduces the shares before the initial public offering
Whether the controlling shareholder or actual controller intends to reduce the shares before the initial public offering □ yes √ no
4、 Relevant risk tips (I) uncertain risks of the implementation of the reduction plan, such as the preconditions and restrictive conditions for the implementation of the plan, as well as the specific conditions for the achievement or elimination of relevant conditions, etc
This reduction plan is the reduction of the company’s shareholders according to their own arrangements, and will not have a significant impact on the company’s governance structure and sustainable operation. During the reduction period, the shareholders who plan to reduce their holdings will choose whether to implement and how to implement the reduction plan according to the market conditions, the company’s share price and other factors. There are uncertainties such as the reduction time, quantity and price. (II) whether the implementation of the share reduction plan may lead to the risk of change in the control of the listed company □ yes √ no (III) other risk tips
1. The share reduction plan complies with the securities law of the people’s Republic of China, the Listing Rules of the Shanghai Stock Exchange on the science and innovation board, the detailed rules for the implementation of share reduction by shareholders, directors, supervisors and senior managers of listed companies on the Shanghai Stock Exchange, and the special provisions on share reduction by shareholders of venture capital funds of listed companies In accordance with the relevant provisions of relevant laws, regulations and normative documents such as the detailed rules for the implementation of share reduction of venture capital funds of Listed Companies in Shanghai Stock Exchange, there is no situation that shares shall not be reduced.
2. During the implementation of the reduction plan, the above shareholders will implement the reduction in strict accordance with the provisions of laws, regulations, departmental rules, normative documents and relevant regulatory requirements, and timely fulfill the obligation of information disclosure.
Please invest rationally and pay attention to investment risks.
It is hereby announced.
Allgens Medical Technology Co.Ltd(688613) board of directors may 23, 2022
